NOVEL ANILINE DERIVATIVES

• Main Authors: WELLER, THOMAS, ACKERMANN, JEAN, AEBI, JOHANNES, WALLBAUM, SABINE, CHUCHOLOWSKI, ALEXANDER, DEHMLOW, HENRIETTA, MORAND, OLIVIER
• Format: Patent
• Language: English; French
• Published: 24.01.2002
• Edition: 7
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salt and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemmia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes. The present invention relates to compounds of formula (I): wherein U, Y, V, W, L, X, A , A , A , A , A and A are as defined in the description and claims and pharmaceutically acceptable salt and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemmia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes. La présente invention concerne des composés représentés par la formule (I). Dans cette formule, U, Y, V, W, L, X, A , A , A , A , A et A sont tels que définis dans la description et les revendications. L'invention concerne également des sels et/ou esters pharmaceutiquement admis de ces composés. Les composés de l'invention conviennent pour le traitement et/ou la prévention d'affections associées à la 2,3-oxydosqualène-lanostérol cyclase telles que l'hypercholestérolémie, l'hyperlipémie, l'artériosclérose, les affections vasculaires, les mycoses, les parasitoses, les calculs biliaires, les tumeurs et/ou les troubles hyperproliférants, et/ou le traitement et/ou la prévention des intolérances au glucose et le diabète.